Carbocisteine-13C3-1,1391068-1

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Carbocisteine-13C3-1

品牌：MedChemExpress (MCE)

货号：HY-D0205AS1

CAS：1391068-19-1

Synonyms：Carbocysteine-13C3-1

存储条件：请将产品存放在分析证书上推荐的条件下。

运输条件：美国大陆的室温；其他地方可能有所不同。

产品活性：Carbocisteine-13C3-1 (Carbocysteine-13C3-1) 是 13C 标记的 Carbocisteine. Carbocisteine 是一种具有口服活性的粘液溶解剂。Carbocisteine 可减轻 NF-κB p65 和ERK1/2 的磷酸化。Carbocisteine 调节 Nrf2/HO-1 和 NFκB 相互作用。Carbocisteine 抑制凋亡(Apoptosis)。Carbocisteine 可用于慢性阻塞性肺疾病 (COPD) 的研究。

生物活性：羧甲司坦-13C3-1（羧甲司坦-13C3-1）是13C标记的羧甲司坦。羧甲司坦是一种口服活性黏液溶解剂。羧甲司坦可减弱NF-κB p65和ERK1/2的磷酸化。羧甲司坦调节Nrf2/HO-1与NFκB的相互作用。羧甲司坦可抑制细胞凋亡。羧甲司坦用于慢性阻塞性肺病(COPD)研究[1][2][3][4][5][6][7][8][9][10][11][12][13]。

体外：氢、碳和其他元素的稳定重同位素已被掺入药物分子中，主要用作药物开发过程中定量的示踪剂。氘化因其可能影响药物的药代动力学和代谢特征而受到关注。

详情参考：www.medchemexpress.cn/carbocisteine-13c3-1.html

参考文献：

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
[2]. Yageta Y, et al. Carbocisteine reduces virus-induced pulmonary inflammation in mice exposed to cigarette smoke. Am J Respir Cell Mol Biol. 2014 May;50(5):963-73.
[3]. Inoue M, et al. Carbocisteine promotes phagocytosis of apoptotic cells by alveolar macrophages. Eur J Pharmacol. 2012 Feb 29;677(1-3):173-9.
[4]. Wang W, et al. Carbocisteine attenuates hydrogen peroxide-induced inflammatory injury in A549 cells via NF-κB and ERK1/2 MAPK pathways. Int Immunopharmacol. 2015 Feb;24(2):306-313.
[5]. Yamaya M, et al. Inhibitory effects of carbocisteine on type A seasonal influenza virus infection in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2010 Aug;299(2):L160-8.
[6]. Hanaoka M, et al. Carbocisteine protects against emphysema induced by cigarette smoke extract in rats. Chest. 2011 May;139(5):1101-1108.
[7]. Abdelhamid AM, et al. Carbocisteine as a Modulator of Nrf2/HO-1 and NFκB Interplay in Rats: New Inspiration for the Revival of an Old Drug for Treating Ulcerative Colitis. Front Pharmacol. 2022 Jun 8;13:887233.
[8]. Song Y, et al. Carbocisteine inhibits the expression of Muc5b in COPD mouse model. Drug Des Devel Ther. 2019 Sep 16;13:3259-3268.
[9]. Song Y, et al. A mucoactive drug carbocisteine ameliorates steroid resistance in rat COPD model. Pulm Pharmacol Ther. 2016 Aug;39:38-47.
[10]. Ishibashi Y, et al. Effects of carbocisteine on altered activities of glycosidase and glycosyltransferase and expression of Muc5ac in SO2-exposed rats. Eur J Pharmacol. 2004 Mar 8;487(1-3):7-15.
[11]. Song Y, et al. Carbocysteine restores steroid sensitivity by targeting histone deacetylase 2 in a thiol/GSH-dependent manner. Pharmacol Res. 2015 Jan;91:88-98.
[12]. Yoshida M, et al. Carbocisteine inhibits oxidant-induced apoptosis in cultured human airway epithelial cells. Respirology. 2009 Sep;14(7):1027-34.
[13]. Wang W, et al. Carbocisteine attenuates TNF-α-induced inflammation in human alveolar epithelial cells in vitro through suppressing NF-κB and ERK1/2 MAPK signaling pathways. Acta Pharmacol Sin. 2016 May;37(5):629-36.
[14]. Paola Rogliani, et al. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Respir Res. 2019 May 27;20(1):104.